
Bacteriophages

David R. Harper • Stephen T. Abedon •
Benjamin H. Burrowes •
Malcolm L. McConville
Editors

Bacteriophages

Biology, Technology, Therapy

Volume 2

With 173 Figures and 44 Tables



Springer

Editors

David R. Harper
Evolution Biotechnologies
Bedfordshire, UK

Stephen T. Abedon
Department of Microbiology
The Ohio State University
Mansfield, OH, USA

Benjamin H. Burrowes
Evolution Biotechnologies
Georgetown, TX, USA

Malcolm L. McConville
Evolution Biotechnologies
Bedfordshire, UK

ISBN 978-3-319-41985-5

ISBN 978-3-319-41986-2 (eBook)

ISBN 978-3-319-41987-9 (print and electronic bundle)

<https://doi.org/10.1007/978-3-319-41986-2>

© Springer Nature Switzerland AG 2021

All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG.
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

As the ongoing crisis of antimicrobial resistance (AMR) threatens to bring an end to the era of routine control of bacterial diseases, there is great interest in developing other approaches to controlling such infections. One of the oldest of these, the use of bacteriophages (viruses that can target and destroy bacteria) as therapeutic agents, is experiencing a resurgence of interest and is now considered a promising approach to countering AMR. First developed 100 years ago, this approach, known as phage therapy, was set aside in Western Europe and the USA when the use of chemical antibiotics became widespread. Now, the pressing need for new ways to control such resistant bacteria is resulting in very real and rapid progress in developing phage therapy, alongside a range of technologies based around bacteriophages, in medicine and elsewhere.

Bacteriophages: Biology, Technology, Therapy is intended to cover all major, current aspects of work with bacteriophages, from their basic biology to clinical trials of phage therapeutics and from early history to nanotechnology. In so doing, the intention is to provide a single, readily citable source covering the biology of bacteriophages and bacteriophage infection, their use across a wide range of technologies, and their evolving use as therapeutic agents.

Contents

Volume 1

Part I Introduction to Bacteriophages: Biology, Technology, Therapy	1
Introduction to Bacteriophages	3
David R. Harper	
Part II Bacteriophage Biology	17
Structure and Function of Bacteriophages	19
Marta Sanz-Gaitero, Mateo Seoane-Blanco, and Mark J. van Raaij	
Adsorption: Phage Acquisition of Bacteria	93
John J. Dennehy and Stephen T. Abedon	
Temperate Phages, Prophages, and Lysogeny	119
Joanna Łoś, Sylwia Zielińska, Anna Krajewska, Zalewska Michalina, Aleksandra Małachowska, Katarzyna Kwaśnicka, and Marcin Łoś	
Bacteriophage-Mediated Horizontal Gene Transfer: Transduction	151
Christine L. Schneider	
Genetics and Genomics of Bacteriophages	193
Aidan Casey, Aidan Coffey, and Olivia McAuliffe	
Bacteriophage Discovery and Genomics	219
Graham F. Hatfull	
Bacteria-Phage Antagonistic Coevolution and the Implications for Phage Therapy	231
Michael A. Brockhurst, Britt Koskella, and Quan-Guo Zhang	
Bacteriophage Ecology	253
John J. Dennehy and Stephen T. Abedon	

Bacteriophage Pharmacology and Immunology	295
Krystyna Dąbrowska, Andrzej Górski, and Stephen T. Abedon	
Phage Infection and Lysis	341
John J. Dennehy and Stephen T. Abedon	
Part III History of Bacteriophages	385
The Discovery of Bacteriophages and the Historical Context	387
William C. Summers	
Early Therapeutic and Prophylactic Uses of Bacteriophages	401
Nina Chanishvili and Zemphira Alavidze	

Volume 2

Part IV Bacteriophage Technology	431
Isolation of Bacteriophages	433
Frits van Charante, Dominique Holtappels, Bob Blasdel, and Benjamin H. Burrowes	
Bacteriophage Use in Molecular Biology and Biotechnology	465
Nathan Brown and Chris Cox	
Detection of Bacteriophages: Phage Plaques	507
Stephen T. Abedon	
Detection of Bacteriophages: Statistical Aspects of Plaque Assay	539
Stephen T. Abedon and Tena I. Katsaounis	
Detection of Bacteriophages: Electron Microscopy and Visualisation	561
David M. Belnap	
Detection of Bacteriophages: Sequence-Based Systems	621
Siân V. Owen, Blanca M. Perez-Sepulveda, and Evelien M. Adriaenssens	
Novel Approaches for Detection of Bacteriophage	645
Carrie L. Pierce, Jon C. Rees, and John R. Barr	
Bacteriophages in Nanotechnology: History and Future	657
Paul Hyman and Jenna Denyes	
The Selection and Optimization of Phage Hosts	689
Jason J. Gill	
Bacteriophage Manufacturing: From Early Twentieth-Century Processes to Current GMP	699
Krzysztof Regulski, Patrick Champion-Arnaud, and Jérôme Gabard	

Intellectual Property Issues for Bacteriophages	731
Martin R. MacLean and David R. Harper	
Bacteriophage as Biocontrol Agents	751
David R. Harper	
Part V Agriculture, Food, and Environmental Use of Bacteriophages	767
Bacteriophages as Bio-sanitizers in Food Production and Healthcare Settings	769
Sudhakar Bhandare and Lawrence Goodridge	
Biofilm Applications of Bacteriophages	789
Catarina Milho, Maria Daniela Silva, Sanna Sillankorva, and David R. Harper	
Industrial Processes Involving Bacteriophages	823
Marcin Łoś	
Crop Use of Bacteriophages	839
Jeffrey B. Jones, Antonet M. Svircev, and Aleksa Ž. Obradović	
Food Safety	857
Lars Fieseler and Steven Hagens	
Bacteriophage Utilization in Animal Hygiene	891
Sarah Klopatек, Todd R. Callaway, Tryon Wickersham, T. G. Sheridan, and D. J. Nisbet	
Part VI Therapeutic Use of Bacteriophages	919
Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia	921
Ryszard Międzybrodzki, Naomi Hoyle, Fikria Zhvaniya, Marzanna Łusiak-Szelachowska, Beata Weber-Dąbrowska, Małgorzata Łobocka, Jan Borysowski, Zemphira Alavidze, Elizabeth Kutter, Andrzej Górska, and Lasha Gogokhia	
The Use of Bacteriophages in Veterinary Therapy	953
Robert J. Atterbury and Paul A. Barrow	
Enzybiotics: Endolysins and Bacteriocins	989
Ryan D. Heselpoth, Steven M. Swift, Sara B. Linden, Michael S. Mitchell, and Daniel C. Nelson	
Phage Display Technology and the Development of Phage-Based Vaccines	1031
Joe A. Fralick and Jason Clark	

Phage Therapy Collaboration and Compassionate Use	1069
Jessica C. Sacher and Jan Zheng	
Clinical Trials of Bacteriophage Therapeutics	1099
Shawna McCallin and Harald Brüssow	
Selection of Disease Targets for Phage Therapy	1129
David R. Harper	
Regulatory Considerations for Bacteriophage Therapy	
Products: USA	1151
Roger D. Plaut and Scott Stibitz	
Regulatory Aspects of the Therapeutic Use of Bacteriophages:	
Europe	1165
Eric Pelfrene, Zigmars Sebris, and Marco Cavaleri	
Index	1179

About the Editors

Dr. David R. Harper has a scientific background in virology and microbiology and is the CEO of Evolution Biotechnologies. He was the founder, CEO, and CSO of Biocontrol Limited and CSO of AmpliPhi Biosciences and managed the first modern regulated clinical trial to demonstrate the efficacy of bacteriophages. He is a member of the Alternatives to Antibiotics panel, a collaboration between the Wellcome Trust and the UK Department of Health.

Dr. Stephen T. Abedon has been a member of the faculty of the Ohio State University, Department of Microbiology, for over 25 years. He has been studying bacteriophages for 35-plus years and has over 100 phage-based publications including 9 monographs or equivalents on phages which he has edited (1), co-edited (7), or single authored (1), along with 3 more edited volumes currently in progress. Additional information and resources can be found at abedon.phage.org.

Dr. Benjamin H. Burrowes received his Ph.D. in medical microbiology from Texas Tech University Health Sciences Center in 2010, where his research focus was the development of therapeutic bacteriophages with extended host range using in vitro evolution. Upon leaving Texas, Dr. Burrowes worked at Biocontrol Inc. (now AmpliPhi Biosciences Corporation) developing multiple human phage therapy preparations targeting several major bacterial pathogens. Ben left GeneWEAVE some time ago and now works as Senior Consultant at Evolution Biotechnologies, Georgetown, TX, USA, working on novel phage therapeutics, and as a Senior Scientist at the Center for Phage Technology, Texas A&M University, College Station, TX, USA.

Dr. Malcolm L. McConville is a microbiologist with over 30 years industrial experience. Having gained a B.Sc. (Cardiff University, UK) and Ph.D. (University of Reading, UK), he has worked in the contract biomedical research industry and for AmpliPhi Biosciences Corporation (formerly Biocontrol Ltd) on the commercial development of bacteriophage therapy products. He is currently Trials Director at Evolution Biotechnologies.

Contributors

Stephen T. Abedon Department of Microbiology, The Ohio State University, Mansfield, OH, USA

Evelien M. Adriaenssens Microbiology Research Group, Institute of Integrative Biology, University of Liverpool, Liverpool, UK

Zemphira Alavidze Phage Therapy Center, Tbilisi, Georgia
Eliava BioPreparations, Tbilisi, Georgia

Robert J. Atterbury School of Veterinary Medicine and Science, University of Nottingham, Leicestershire, UK

John R. Barr Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

Paul A. Barrow School of Veterinary Medicine and Science, University of Nottingham, Leicestershire, UK

David M. Belnap School of Biological Sciences and Department of Biochemistry, University of Utah, Salt Lake City, UT, USA

Sudhakar Bhandare Department of Food Science, McGill University, Montreal, QC, Canada

Bob Blasdel Laboratory of Gene Technology, Leuven, Belgium
Vésale Pharma, Noville-Sur-Mehaigne, Belgium

Jan Borysowski Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland

Michael A. Brockhurst Department of Animal and Plant Sciences, University of Sheffield, Sheffield, UK
University of York, York, UK

Nathan Brown Department of Infection, Immunity, and Inflammation, University of Leicester, Leicester, UK

Harald Brüssow Host-Microbiome Interaction Group, Institute of Nutritional Science, Nestlé Research Center, Lausanne, Switzerland

Benjamin H. Burrowes Evolution Biotechnologies, Georgetown, TX, USA

Todd R. Callaway Department of Animal and Dairy Science, University of Georgia, Athens, GA, USA

Aidan Casey Department of Food Biosciences, Teagasc Food Research Centre, Cork, Ireland

Marco Cavaleri Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency, Amsterdam, The Netherlands

Patrick Champion-Arnaud Pherecydes Pharma SA, Romainville, France

Nina Chanishvili George Eliava Institute of Bacteriophage, Microbiology and Virology (EIBMV), Tbilisi, Georgia

Jason Clark Fixed-Phage Ltd, Glasgow, UK

Aidan Coffey Department of Biological Sciences, Cork Institute of Technology, Cork, Ireland

Chris Cox Cobio Diagnostics, Golden, CO, USA

Krystyna Dąbrowska Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

John J. Dennehy Biology Department, Queens College and The Graduate Center of the City University of New York, New York, NY, USA

Jenna Denyes NSPM, Meggen, Switzerland

Lars Fieseler Zurich University of Applied Sciences, Institute of Food and Beverage Innovation, Wädenswil, Switzerland

Joe A. Fralick Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA

Jérôme Gabard Pherecydes Pharma SA, Romainville, France

Jason J. Gill Department of Animal Science, Center for Phage Technology, Texas A&M University, College Station, TX, USA

Lasha Gogokhia Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA

Lawrence Goodridge Canadian Research Institute for Food Safety, Department of Food Science, University of Guelph, Guelph, ON, Canada

Andrzej Górski Bacteriophage Laboratory, Phage Therapy Unit, Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Wrocław, Poland

Steven Hagens Microos Food Safety, Gelderland, Wageningen, The Netherlands

David R. Harper Evolution Biotechnologies, Bedfordshire, UK

Graham F. Hatfull Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA

Ryan D. Hesel坡th Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA

Dominique Holtappels Laboratory of Gene Technology, Leuven, Belgium

Naomi Hoyle Eliava Phage Therapy Center, Eliava Foundation, Tbilisi, Georgia

Paul Hyman Department of Biology/Toxicology, Ashland University, Ashland, OH, USA

Jeffrey B. Jones University of Florida, Gainesville, FL, USA

Tena I. Katsaounis Department of Mathematics, The Ohio State University, Mansfield, OH, USA

Sarah Klopatek Department of Animal Science, University of California, Davis, Davis, CA, USA

Britt Koskella Department of Integrative Biology, University of California, Berkeley, Berkeley, CA, USA

Anna Krajewska Department of Bacterial Molecular Genetics, Faculty of Biology, University of Gdańsk, Gdańsk, Poland

Elizabeth Kutter Phagebiotics Research Foundation, Olympia, WA, USA

Katarzyna Kwaśnicka Department of Molecular Biology, Faculty of Biology, University of Gdańsk, Gdańsk, Poland

Sara B. Linden Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA

Małgorzata Łobocka Autonomous Department of Microbial Biology, Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Warsaw, Poland

Department of Microbial Biochemistry, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

Joanna Łoś Department of Bacterial Molecular Genetics, Faculty of Biology, University of Gdańsk, Gdańsk, Poland
Phage Consultants, Gdańsk, Poland

Marcin Łoś Department of Bacterial Molecular Genetics, Faculty of Biology, University of Gdańsk, Gdańsk, Poland
Phage Consultants, Gdańsk, Poland

Marzanna Łusiak-Szelachowska Bacteriophage Laboratory, Hirschfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Martin R. MacLean Mathys and Squire LLP, London, UK

Aleksandra Małachowska Department of Genetics and Biosystematics, Faculty of Biology, University of Gdańsk, Gdańsk, Poland

Olivia McAuliffe Department of Food Biosciences, Teagasc Food Research Centre, Cork, Ireland

Shawna McCallin Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland

Zalewska Michalina Department of Bacterial Molecular Genetics, Faculty of Biology, University of Gdańsk, Gdańsk, Poland

Ryszard Międzybrodzki Bacteriophage Laboratory, Phage Therapy Unit, Hirschfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland

Catarina Milho CEB – Centre of Biological Engineering, LIBRO – Laboratório de Investigação em Biofilmes Rosário Oliveira, University of Minho, Braga, Portugal

Michael S. Mitchell Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA

Daniel C. Nelson Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA

D. J. Nisbet Food and Feed Safety Research Unit, USDA/ARS, College Station, TX, USA

Aleksa Ž. Obradović Faculty of Agriculture, University of Belgrade, Belgrade-Zemun, Serbia

Siân V. Owen Microbiology Research Group, Institute of Integrative Biology, University of Liverpool, Liverpool, UK

Department of Biomedical Informatics and Laboratory of Systems Pharmacology,
Harvard Medical School, Boston, MA, USA

Eric Pelfrene Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency, Amsterdam, The Netherlands

Blanca M. Perez-Sepulveda Microbiology Research Group, Institute of Integrative Biology, University of Liverpool, Liverpool, UK

Carrie L. Pierce Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

Roger D. Plaut Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Jon C. Rees Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

Krzysztof Regulski Pherecydes Pharma SA, Romainville, France

Jessica C. Sacher Phage Directory, Atlanta, GA, USA

Marta Sanz-Gaitero Department of Macromolecular Structure, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain

Christine L. Schneider Carroll University, Waukesha, WI, USA

Zigmars Sebris Regulatory Affairs Office, Human Medicines Evaluation Division, European Medicines Agency, Amsterdam, The Netherlands

Mateo Seoane-Blanco Department of Macromolecular Structure, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain

T. G. Sheridan Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA

Sanna Sillankorva CEB – Centre of Biological Engineering, LIBRO – Laboratório de Investigação em Biofilmes Rosário Oliveira, University of Minho, Braga, Portugal

INL International Iberian Nanotechnology Laboratory, Braga, Portugal

Maria Daniela Silva CEB – Centre of Biological Engineering, LIBRO – Laboratório de Investigação em Biofilmes Rosário Oliveira, University of Minho, Braga, Portugal

Scott Stibitz Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

William C. Summers Yale University, New Haven, CT, USA

Antonet M. Svircev Agriculture and Agri-Food Canada, Vineland Station, ON, Canada

Steven M. Swift Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA

Frits van Charante Ghent University, Ghent, Belgium

Mark J. van Raaij Department of Macromolecular Structure, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain

Beata Weber-Dąbrowska Bacteriophage Laboratory, Phage Therapy Unit, Hirschfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

Tryon Wickersham Department of Animal Science, Texas A&M University, College Station, TX, USA

Quan-Guo Zhang College of Life Sciences, Beijing Normal University, Beijing, China

Jan Zheng Phage Directory, Atlanta, GA, USA

Fikria Zhvaniya Eliava Phage Therapy Center, Eliava Foundation, Tbilisi, Georgia

Sylwia Zielińska Department of Bacterial Molecular Genetics, Faculty of Biology, University of Gdańsk, Gdańsk, Poland

Phage Consultants, Gdańsk, Poland